Norinnova and AstraZeneca join forces to advance health innovation

From left: Guro Bjøntegaard, Country Director at AstraZeneca; Ane Birkeland, Head of Health Incubator at Norinnova; and Kristin Løseth, Medical Director at AstraZeneca.

Norinnova and AstraZeneca, a global leader in the pharmaceutical industry, are entering into a collaboration that will give researchers, startups and growth companies in the health sector access to international industry expertise and and mentoring. The aim is to strengthen the development of new healthcare solutions and help more innovations reach patients and the market sooner.

The collaboration connects Norinnova’s innovation platform with AstraZeneca’s expertise, experience and global network through the AstraZeneca Nordic Exchange Mentoring Program. Through the program, startups and research-based innovation projects affiliated with Norinnova gain access to mentors and industry expertise from AstraZeneca at a stage when decisions about regulatory strategy, markets and clinical direction can be crucial.

Health innovation is characterized by complex development pathways, strict regulatory requirements and the need for an early understanding of both clinical and market conditions. Many promising solutions stall because companies cannot access the right expertise at the right time.

“At Norinnova, we believe collaboration is a driving force for achieving results. Many strong health innovations need more than capital and networks. They need experience from people who know the international landscape and understand which decisions will be crucial along the way. That is why this collaboration is so valuable to the projects and companies we work with. We are very pleased that AstraZeneca wants to help bring more innovative solutions forward.”

— Asbjørn Lilletun, CEO of Norinnova

International expertise at pivotal stages

Through the collaboration, selected companies will have access to dialogue and mentoring with AstraZeneca experts on scientific, regulatory and commercial issues. This provides valuable insight into international requirements and helps companies make better-informed strategic decisions at pivotal stages.

“We see Norinnova as an ambitious and capable innovation community with a clear international perspective. Many promising healthcare solutions face difficult decisions early in their development. Through this collaboration, we want to contribute insight and experience that can help more companies move forward.”

— Kristin Løseth, Medical Director at AstraZeneca Norway


Strengthening Norinnova’s commitment to health

The collaboration with AstraZeneca will be an important part of Norinnova’s commitment to health and will strengthen the offering for startups and growth companies through the Norinnova Health Incubator.

The Health Incubator is for startups and growth companies in areas including pharma and therapeutics, medtech, AI and diagnostics. Through the incubator, companies receive structured support from idea to market, access to advice and expert knowledge, clinical environments, investor networks, and relevant national and international forums.

Norinnova has built an innovation platform over time where healthcare services, academia, startups, investors and international industry work together. The collaboration with AstraZeneca through the AstraZeneca Nordic Exchange Mentoring Program further strengthens the connection to international industry and is an important step in bringing more healthcare solutions from idea to real-world application, benefiting patients and society.

Read more about the incubator here

Ane Birkeland

Have an idea or company in health?

Are you working on a startup, a growth company or a healthcare innovation and would like to learn more about the opportunities through the Norinnova Health Incubator?

Contact Ane Birkeland, Head of the Norinnova Health Incubator ane@norinnova.no